Accepted Manuscript

Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options

Dulce Alfaiate, Paul Dény, David Durantel


PII: S0166-3542(15)00195-3

DOI: http://dx.doi.org/10.1016/j.antiviral.2015.08.009

Reference: AVR 3679

To appear in: Antiviral Research

Received Date: 11 June 2015 Revised Date: 10 August 2015 Accepted Date: 11 August 2015



Please cite this article as: Alfaiate, D., Dény, P., Durantel, D., Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options, *Antiviral Research* (2015), doi: http://dx.doi.org/10.1016/j.antiviral.2015.08.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options

Dulce Alfaiate^{1,2}, Paul Dény^{1,3*}, and David Durantel^{1,2,4,*}

Correspondence:

David Durantel (david.durantel@inserm.fr) and Paul Dény (paul.deny@inserm.fr) Address: INSERM U1052, 151 cours Albert Thomas, 69003 Lyon, France

Phone: + 33 4 72 68 19 70 Fax: +33 4 72 68 19 71

Acknowledgements:

We would like to thank Frédéric Le Gal, Natali Abeywickrama Samarakoon, Jean-Claude Cortay and Camille Sureau for helpful discussions. Dulce Alfaiate was supported by grants from Fundação Calouste Gulbenkian and Fundação para a Ciência e a Tecnologia. DD and PD were supported by grants from ANRS (French national agency for research on AIDS and viral hepatitis; several grants from CSS4), FINOVI (Foundation for innovation in infectiology; project call n°#4), FRM (Foundation for medical research; DEQ20110421327), Hoffmann-La-Roche Ltd (Switzerland division) and by INSERM core grants and interface contract (PD). DD is also supported by the DEVweCAN LABEX (ANR-10-LABX-0061) of the "Université de Lyon", within the program "Investissements d'Avenir" (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR).

¹ INSERM, U1052, CNRS UMR_5286, Cancer Research Centre of Lyon (CRCL), 69008 Lyon, France;

² University of Lyon, Université Claude Bernard (UCBL), 69008 Lyon, France;

³ Université Paris 13, UFR SMBH, Laboratoire de Bactériologie Virologie - Hygiène, GHU Paris Seine Saint Denis, Assistance Publique – Hôpitaux de Paris, Bobiqny, France;

⁴ Labex DEVweCAN, 69008 Lyon, France.

^{*} Contributed equally.

Download English Version:

https://daneshyari.com/en/article/5821837

Download Persian Version:

https://daneshyari.com/article/5821837

<u>Daneshyari.com</u>